Page 1

TELIX PHARMACEUTICALS Results for announcement to the market Current Reporting Period : Previous Reporting Period : Appendix 4D Half - year report for the six months ended 30 June 2021 Revenue from continuing operations Other income : R & D tax incentive income Loss after income tax for the half - year attributable to members Total comprehensive loss for the half year attributable to members NTA backing 30 June 2021 30 June 2020 6 months to 30 June 2021 $ 000 Net tangible asset backing per ordinary security 2,910 4,598 ( 32,514 ) ( 33,436 ) Telix Pharmaceuticals Limited Suite 401 , 55 Flemington Road North Melbourne , VIC , 3051 ABN : 85 616 620 369 6 months to 30 June 2020 $ 000 1,607 5,850 ( 18,301 ) ( 17,622 ) 30 June 2021 $ ( 0.03 ) Movement Movement $ 000 % 1,303 ( 1,252 ) ( 14,213 ) ( 15,814 ) 0.04 81 % ( 21 % ) 78 % 30 June 2020 $ 90 % Events subsequent to the end of the half - year Refer page 8 of the Interim Financial Report for details of events subsequent to 30 June 2021 and at the date of this report . Review of results The Directors ' Report attached to this Appendix 4D details the review of results . This information should be read in conjunction with the most recent Annual Financial Report ( 31 December 2020 ) . Auditor's Review This report is based on the Interim Financial Report for the half - year ended 30 June 2021 of Telix Pharmaceuticals Limited and its controlled entities , which has been reviewed by PricewaterhouseCoopers ( PwC ) . The Independent Auditor's Review Report provided by PwC is included in the Interim Financial Report . The Appendix 4D and Interim Financial Report for the half - year ended 30 June 2021 have been approved for release by the Board of Directors .